MorphoSys has notched another high-profile pharma partnership on its belt of antibody deals, and it's set its sights on immune checkpoint inhibitors. With this pact, Merck KGaA is also staking out a position on the growing roster of companies scrambling to find a profitable place for itself in immuno-oncology.
Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.
The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 antibody currently in a Phase I/IIa clinical trial in multiple myeloma.
Celgene has decisively stepped in to partner on an early-stage myeloma and leukemia drug in MorphoSys's pipeline, paying $92 million upfront, a $60 million premium for a stake in the company and offering to cover a substantial portion of the R&D budget for the antibody targeting the CD38 molecule.
GSK is paying about $28 million of that upfront and will take over all further R&D and commercialization efforts. MorphoSys snags a double-digit royalty stream from any sales that might come along with up to $550 million in milestones.
New clinical data have bolstered MorphoSys CEO Simon Moroney's blockbuster hopes for the biotech's experimental antibody against rheumatoid arthritis (RA), and the chief executive is hunting for a partner to aid in developing the drug that he believes could generate north of $1 billion in annual sales, Reuters reported.
That dark cloud you've been watching form around the late-stage Alzheimer's drug development field has come equipped with a bright silver lining for Roche.
German biotech MorphoSys has had a busy morning. It announced today that its subsidiary Sloning BioTechnology has signed a non-exclusive license and technology transfer agreement with pharma giant
Shares of Belgium's Galapagos surged on the news that it had partnered with Germany's MorphoSys AG to develop antibodies for bone and joint diseases. The two companies plan to jointly invest 30
Daiichi Sankyo is buying Germany's U3 Pharma for $235 million in cash. The Japanese pharma company gains a developer that's been